Can a powerful cholesterol drug make heart plaques safer?
NCT ID NCT06791031
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a PCSK9 inhibitor (a strong cholesterol-lowering drug) to standard statin therapy can stabilize fatty plaques in the arteries of people who recently had a heart attack. About 212 participants will receive either the drug combination or standard care for 6 months. Doctors will use special imaging to measure changes in plaque thickness and composition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) plus moderate-intensity statin
What this could lead to
If successful, this could show that early use of PCSK9 inhibitors helps stabilize dangerous plaques in heart arteries, potentially reducing future heart attack risk.
What could go wrong
This is a small, early-stage trial (212 people) with no placebo control, so results may not be definitive. The study only looks at plaque changes on imaging, not actual heart attacks, so real-world benefit remains uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••